Literature DB >> 18762993

It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting.

Nuriye Yildirim Ozdemir1, Hüseyin Abali, Berna Oksüzoğlu, Burçin Budakoğlu, Ilkay Akmangit, Nurullah Zengin.   

Abstract

GOALS: It is generally recommended to wait for at least 24 h before starting chemotherapy after implanting venous port catheters (VPC). Our aim was to evaluate whether it is safe to start chemotherapy on the day of implantation. PATIENTS AND METHODS: One hundred eighty patients who had to be given chemotherapy on the day of VPC implantation at our institution from June 2005 to April 2007 were included. MAIN
RESULTS: Of patients, 122 were male (67.8%) and median age was 55 years. Majority (133, 72.8%) had colon and gastric adenocancer. Median time to chemotherapy onset from VPC implantation was 102 min (minimum-maximum, 12-402). One hundred sixty-four (91.1%) received prolonged chemotherapy infusions beyond 48 h. No life-threatening acute complications like pneumothorax and hemothorax developed. In one patient extravasation (empty saline extravasation secondary to wrong insertion of the needle), in 17 (9.4%) pain, and in 41 (22.8%) minor bleeding as echymosis were seen. Thrombosis developed in 11 (6.1%). Reasons for VPC removal were thrombosis (2), sepsis (2), cellulitis (1), skin dehiscence (1), and patient will (1).
CONCLUSION: Chemotherapy administration immediately after VPC implantation appears safe without increased acute and chronic complications in inpatient setting.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18762993     DOI: 10.1007/s00520-008-0498-x

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  19 in total

1.  A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.

Authors:  E E Vokes; R L Schilsky; K E Choi; D M Magid; C M Guarnieri; S M Whaling; M J Ratain; R R Weichselbaum; W R Panje
Journal:  Cancer       Date:  1989-01-01       Impact factor: 6.860

2.  Mode of chemotherapy does not affect complications with an implantable venous access device.

Authors:  D F Brown; M J Muirhead; P M Travis; S R Vire; J Weller; M Hauer-Jensen
Journal:  Cancer       Date:  1997-09-01       Impact factor: 6.860

3.  Central venous thrombosis: an early and frequent complication in cancer patients bearing long-term silastic catheter. A prospective study.

Authors:  M De Cicco; M Matovic; L Balestreri; G Panarello; D Fantin; S Morassut; V Testa
Journal:  Thromb Res       Date:  1997-04-15       Impact factor: 3.944

4.  Totally implantable central venous access ports for long-term chemotherapy. A prospective study analyzing complications and costs of 333 devices with a minimum follow-up of 180 days.

Authors:  R Biffi; F de Braud; F Orsi; S Pozzi; S Mauri; A Goldhirsch; F Nolè; B Andreoni
Journal:  Ann Oncol       Date:  1998-07       Impact factor: 32.976

5.  Catheter-related infection and thrombosis of the internal jugular vein in hematologic-oncologic patients undergoing chemotherapy: a prospective comparison of silver-coated and uncoated catheters.

Authors:  Christoph Harter; Hans Jürgen Salwender; Alfons Bach; Gerlinde Egerer; Hartmut Goldschmidt; Anthony D Ho
Journal:  Cancer       Date:  2002-01-01       Impact factor: 6.860

6.  Catheter tip position as a risk factor for thrombosis associated with the use of subcutaneous infusion ports.

Authors:  Jo Caers; Christel Fontaine; Vincent Vinh-Hung; Johan De Mey; Gerrit Ponnet; Chris Oost; Jan Lamote; Jacques De Greve; Benjamin Van Camp; Patrick Lacor
Journal:  Support Care Cancer       Date:  2004-11-05       Impact factor: 3.603

7.  Radiology-assisted placement of implantable subcutaneous infusion ports for long-term venous access.

Authors:  S L Morris; P F Jaques; M A Mauro
Journal:  Radiology       Date:  1992-07       Impact factor: 11.105

8.  Classical external indwelling central venous catheter versus totally implanted venous access systems for chemotherapy administration: a randomized trial in 100 patients with solid tumors.

Authors:  P Carde; M F Cosset-Delaigue; A Laplanche; I Chareau
Journal:  Eur J Cancer Clin Oncol       Date:  1989-06

9.  Schedule-selective biochemical modulation of 5-fluorouracil: a phase II study in advanced colorectal cancer.

Authors:  A F Sobrero; C Aschele; A P Guglielmi; A M Mori; L M Tixi; E A Bolli; R Rosso; S Mammoliti; G A Rollandi; S Bertoglio
Journal:  Clin Cancer Res       Date:  1995-09       Impact factor: 12.531

Review 10.  Long-term outcome of radiological-guided insertion of implanted central venous access port devices (CVAPD) for the delivery of chemotherapy in cancer patients: institutional experience and review of the literature.

Authors:  J Vardy; K Engelhardt; K Cox; J Jacquet; A McDade; M Boyer; P Beale; M Stockler; R Loneragan; B Dennien; R Waugh; S J Clarke
Journal:  Br J Cancer       Date:  2004-09-13       Impact factor: 7.640

View more
  6 in total

1.  Is there any effect of first-day usage of a totally implantable venous access device on complications?

Authors:  Hasan Karanlik; Hatice Odabas; Ilknur Yildirim; Ilker Ozgur; Berkay Kilic; Fatma Sen; Sidika Kurul; Adnan Aydiner
Journal:  Int J Clin Oncol       Date:  2015-04-25       Impact factor: 3.402

Review 2.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

3.  Effect of port-care frequency on venous port catheter-related complications in cancer patients.

Authors:  Hatice Odabas; Nuriye Yıldırım Ozdemir; Ipek Ziraman; Sercan Aksoy; Huseyin Abali; Berna Oksuzoglu; Metin Isik; Burak Civelek; Dogan Dede; Nurullah Zengin
Journal:  Int J Clin Oncol       Date:  2013-08-27       Impact factor: 3.402

4.  Comparison of subcutaneous central venous port via jugular and subclavian access in 347 patients at a single center.

Authors:  Bilgin Kadri Aribaş; Kemal Arda; Ozge Aribaş; Nazan Ciledağ; Zeynel Yoloğlu; Elif Aktaş; Turgut Seber; Seyhmus Kavak; Yusuf Coşar; Hidir Kaygusuz; Ekrem Tekin
Journal:  Exp Ther Med       Date:  2012-07-30       Impact factor: 2.447

5.  Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer.

Authors:  Jie Zhou; Shikun Qian; Weixing He; Guodong Han; Hongsheng Li; Rongcheng Luo
Journal:  World J Surg Oncol       Date:  2014-12-08       Impact factor: 2.754

6.  Utility of totally implantable venous access ports in patients with breast cancer.

Authors:  Peng Zhang; Jun Du; Changsheng Fan; Xueli Mo; Jie Dong; Zhenhua Fan; Qikang Zhao
Journal:  Breast J       Date:  2019-09-20       Impact factor: 2.431

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.